Since one of the molecular characteristics of neurodegenerative diseases consists of the presence of insoluble protein aggregates, whose accumulation is often a TG2-dependent phenomenon, this is paving the way to the potential use of TG2 inducers and/or inhibitors as new therapeutic tools to treat such diseases [11,12,14,92,107]. Here, TGM2 is linked to neurodegenerative disease.